

# NEW CLINICAL PERSPECTIVES OF CTCs IN THE ERA OF PRECISION MEDICINE

## CO-CHAIRS:

### Massimo Cristofanilli, MD

Robert H Lurie Comprehensive Cancer Center,  
Feinberg School of Medicine, Chicago, IL

### Wolfgang Janni, MD

University of Ulm, Germany


## FACULTY:

### Jean-Yves Pierga, MD, PhD

Institut Curie & Université Paris Descartes, France

### Johann De Bono, MD, PhD

The Institute of Cancer Research and Royal Marsden, London, UK



**SATURDAY,  
SEPTEMBER 28 | 18:30 - 20:00**  
**SANTANDER AUDITORIUM, HALL 3,  
FIRA GRAN VIA, BARCELONA, SPAIN**

## OBJECTIVES:

- Review the clinical data supporting the prognostic value of CTCs enumeration in early and advanced breast cancer.
- Review the clinical data supporting the prognostic role of CTCs enumeration in advanced prostate cancer.
- Summarize current evidence and provide recommendation for CTCs enumeration use in the routine care of patients with advanced breast and prostate cancer.

## PROGRAMME:

### 18:30-18:45

A single baseline CTC count for staging of metastatic Breast Cancer: Beyond anatomical description - M Cristofanilli

### 18:45-19:00

Prognostic and predictive value of CTC count in the management of HR+ Metastatic Breast Cancer - JY Pierga

### 19:00-19:15

Prognostic role of CTC detection in HR+ Early Breast Cancer - W Janni

### 19:15-19:30

CTC count and single cells evaluation in metastatic Prostate Cancer - J De Bono

### 19:30-20:00

The current value of CTCs in patients' management (**Roundtable**)